背景:由于使用免疫抑制剂,肺移植受者的2019年冠状病毒病(COVID-19)感染可能是致命的。可以向这些患者施用抗病毒剂。联合包装的尼马特雷韦-利托那韦是目前正在组合使用的新药物。
方法:在本报告中,我们展示了一个64岁女性的案例,肺移植接受者,谁经历了低钠血症,并显示了高血清他克莫司浓度后,共同包装的尼马特雷韦-利托那韦组合给药。
结论:虽然尼马特雷韦-利托那韦和他克莫司联合用药并非禁忌,应首先考虑其他治疗策略,如果可用,使用尼马特雷韦-利托那韦组合时应减少他克莫司的剂量。在需要联合治疗的情况下,肺移植受者应密切监测他克莫司血清水平.更多此类报告的文档对于确定尼马特雷韦-利托那韦与其他药物之间的药物相互作用非常重要,目的是防止严重的不良反应。
BACKGROUND: Coronavirus disease 2019 (COVID-19) infection in lung transplant recipients can be lethal owing to the use of immunosuppressants. Antiviral agents may be administered to these patients. Co-packaged nirmatrelvir-ritonavir is a new agent currently being used in combination.
METHODS: In this report, we present a
case of a 64-year-old woman, a lung transplant recipient, who experienced hyponatremia and showed a high serum tacrolimus concentration following the administration of the co-packaged nirmatrelvir-ritonavir combination.
CONCLUSIONS: Although the nirmatrelvir-ritonavir and tacrolimus combination is not contraindicated, other treatment strategies should be considered first, if available, and the dose of tacrolimus should be reduced when using the nirmatrelvir-ritonavir combination. In cases where combination therapy is necessary, serum tacrolimus levels should be closely monitored in lung transplant recipients. Documentation of more such
reports is important to identify drug interactions between nirmatrelvir-ritonavir and other agents, with the aim of preventing severe adverse effects.